AVXL
Anavex Life Sciences Corp.
6.78
USD
This page is just a preview of the data found in TrendSpider’s full version
Anavex Life Sciences Corp. stock is up 23.27% since 30 days ago. The next earnings date is Feb 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 9 PUTs, 1 CALL. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 13 Oct 16:22 | 19 Jan, 2024 | 6.00 | 181 | ||
| 31 Oct 15:03 | 17 Nov, 2023 | 7.00 | 711 | ||
| 02 Nov 15:11 | 19 Jan, 2024 | 7.00 | 408 | ||
| 09 Nov 19:55 | 17 Nov, 2023 | 5.00 | 14706 | ||
| 10 Nov 16:42 | 19 Jan, 2024 | 5.00 | 458 | ||
| 20 Nov 15:05 | 19 Jan, 2024 | 5.00 | 2206 | ||
| 22 Nov 20:52 | 19 Apr, 2024 | 9.00 | 0 | ||
| 24 Nov 16:03 | 19 Jan, 2024 | 5.00 | 4424 | ||
| 24 Nov 16:35 | 19 Jan, 2024 | 5.00 | 4424 | ||
| 24 Nov 16:38 | 19 Jan, 2024 | 5.00 | 4424 |
Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.
